In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

QLT acquires Atrix Labs

Executive Summary

Under terms of a tax-free reorganization, specialty pharmaceuticals company QLT Inc. will acquire fellow specialty pharma and drug delivery company Atrix Laboratories for about $789mm. In exchange for each Atrix share, QLT will give one of its common shares plus $14.61 in cash; this total share price of $37.45 is a 34% premium to Atrix's market average.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies